Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034619 | A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. | PHASE2 | COMPLETED | - | — | — | - | - | Jul 19, 2006 | 22 | United States |
| NCT00034502 | A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | PHASE1 | COMPLETED | - | — | — | - | - | Jul 19, 2006 | 9 | United States, Germany |
| Name | Type | Description |
|---|---|---|
| ALIMTA | DRUG | - |
| Oxaliplatin | DRUG | - |
| irinotecan | DRUG | - |
Inclusion Criteria: * Diagnosis of primary cancer of the colon or rectum * Must have measurable disease * Must be able to comply with study procedure Exclusion Criteria: * Prior chemotherapy for advanced disease * Pregnancy or lactation * Candidates for surgical resection of one or more metastati...